DOI: https://doi.org/10.22263/2312-4156.2017.4.24
Zherulik S.V., Lud N.G., Generalov I.I.
Clinical implementation of polyclonal catalytic antibodies: possibilities and prospects
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2017;16(4):24-36.
Abstract.
The article presents the modern data on antibodies demonstrating catalytic (abzyme) activity. The main basic types of enzymatic activity of antibodies, such as nuclease, proteolytic and oxidoreductase are described. The newest theories of participation of polyclonal abzymes in the pathogenesis of allergic, autoimmune, infectious, tumor and other pathologies are summarized. The interplay of various types of abzyme activity with clinical manifestations and disease prognosis is described. The catalytic activity of IgA, IgG and IgM in different biological media, such as breast milk and oral fluid is presented as well. The possibilities of clinical use of polyclonal abzymes for differential diagnosis of diseases and the creation of a new generation of drugs for the application in various fields of medicine are analyzed, and the advantages of manufacturing efficient polyclonal preparations of catalytic antibodies in comparison with monoclonal abzymes are discussed.
Key words: abzymes, polyclonal catalytic antibodies, autoantibodies, pathogenesis, laboratory diagnosis of diseases.
References
1. Pauling L. Molecular Architecture and Biological Reactions. Chem Eng News. 1946;24(10):1375-7. doi: http://dx.doi.org/10.1021/cen-v024n010.p1375
2. Slobin LI. Preparation and some properties of antibodies with specificity toward p-Nitrophenyl esters. Biochemistry. 1966;5(9):2836-44. doi: http://dx.doi.org/10.1021/bi00873a009
3. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986 Dec;234(4783):1566-70.
4. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989 Jun;244(4909):1158-62.
5. Smirnov IV, Golovin AV, Chatziefthimiou SD, Stepanova AV, Peng Y, Zolotareva OI, et al. Robotic QM/MM-driven maturation of antibody combining sites. Sci Adv. 2016 Oct; 2(10): e1501695. doi: http://dx.doi.org/10.1126/sciadv.1501695
6. Kul’berg AYa, Docheva YuV, Tarkhanov IA, Spivak VA. About proteolytic activity in drugs of the cleaned immunoglobulin of G and antibodies of a rabbit. Biokhimiia. 1969;34(6):1178-83. (In Russ.)
7. Shuster AM, Gololobov GV, Kvashuk OA, Gabibov AG. Idiotypic and natural catalytically active antibodies. Molekuliar Biologiia. 1991;25(3):593-602. (In Russ.)
8. Generalov II, Azarenok KS, Dotsenko EA, Okulich VK. Some aspects of an immune response on Hyaluronidasum as a factor of aggression of microorganisms. V: Aktual’nye voprosy patogeneza i terapii infektsionnykh i parazitarnykh boleznei. Leningrad, RF; 1987. Р. 10-6. (In Russ.)
9. Suchkov SV. Catalytic antibodies and their value for applied medicine. Al’m Klin Meditsiny. 2003;(6):387-91. (In Russ.)
10. Vodounon CA, Abramova ZI, Chabi CB, Kurbanov RA, Reshetnikova DI, Skibo YV, et al. Role of autoantibody in the pathogenesis of patients with atopic bronchial asthma. J Immunol. 2015;8(1):1-16. doi: http://dx.doi.org/10.3923/rji.2015.1.16
11. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. DNA-hydrolyzing autoantibodies. Science. 1992 May;256(5057):665-7.
12. Buneva VN, Andrievska OA, Romannikova IV. Interaction of catalytically active antibodies with oligoribonucleotides. Molekuliar Biologiia. 1994;28(4):739-43. (In Russ.)
13. Generalov II. Abzimny activity of immunoglobulins. Vitebsk, RB: VGMU; 2000. 152 р. (In Russ.)
14. Suchkov SV, Gabibov AG, Gnuchev NV. DNK-abzimy and cytotoxicity mechanisms at a systemic lupus erythematosus. Immunologiia. 2001;(4):47-51. (In Russ.)
15. Sabirzyanova AZ, Nevzorova TA. Cytotoxicity and genotoxicity of antibodies to native deoxyribonucleic acid in systemic lupus erythematosus and rheumatoid arthritis. Ros Immunol Zhurn. 2013;7(4):428-36. (In Russ.)
16. Volkova MV, Kunder EV, Generalov II. Nucleara activity of polyclonal immunoglobulin G in patients with early rheumatoid arthritis. Immunopatologiia Allergologiia Infektologiia. 2012;(1):12-8. (In Russ.)
17. Piven’ NV, Burakovskiy AI, Lukhverchik LN. Pathogenetic role of autoantitelabzim at organospetsifichesky autoimmune pathology. Med Immunologiia. 2011;13(2-3):145-50. (In Russ.)
18. Suchkov SV, Alekberova ZS, Khitrov AN, Shogenov ZS, Voskresenskaya OV, Gnuchev NV, i dr. Achievements and prospects of a clinical abzimologiya. Med Immunologiia. 2006;8(1):23-30. (In Russ.)
19. Baz K,Cimen MY, Kokturk A, Yazici AC, Eskandari G, Ikizoglu G, et al. Oxidant / antioxidant status in patients with psoriasis. Yonsei Med J. 2003 Dec;44(6):987-90. doi: http://dx.doi.org/10.3349/ymj.2003.44.6.987
20. Kunder EV, Litvyakov AM, Zykova OS, Generalov II, Volkova MV. The catalytic activity of IgG with isolated cutaneous psoriasis, psoriatic onychodystrophy and arthropathic psoriasis. Vestn VGMU. 2007;6(2):56-61. (In Russ.)
21. Mal’tsev KA, Khitroe AI, Vvedenskaya OYu, Ponomarenko NA, Isaeva MA, Kimova MV, i dr. Catalytic autoantibodies – the new molecular tool in a cardiology and an ophthalmology. Terapevt Arkhiv. 2006;78(11):70-5. (In Russ.)
22. Williamson RA, Burgoon MP, Owens GP, Ghausi O, Leclerc E, Firme L, et al. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Feb;98(4):1793-8. doi: http://dx.doi.org/10.1073/pnas.031567598
23. Sepiashvili RI, Salafet OV, Kimova MV, Kalinina EV, Martynov LA, Neuhaus O, i dr. Antibodies in a pathogenesis of demyelinating diseases of the autoimmune nature. Allergologiia Immunologiia. 2010;11(1):20-30. (In Russ.)
24. Kalinina EV, Ponamarenko NA, Durov OM, Peleev FN, Vorob’yev II, Kekenadze NN, i dr. Catalytic autoantibodies at an autoimmune myocarditis: clinical and pathogenetic importance. Terapevt Arkhiv. 2005;77(9):65-70. (In Russ.)
25. Kekenadze NN, Kalinina EV, Shogenov ZS, Paleev FN, Zemtsova ME, Gabibov AG, i dr. The possible pathogenetic and clinical importance of autoantibodies at virus myocardites. Kardiovaskuliarn Terapiia Profilaktika. 2005;4(4-S):156. (In Russ.)
26. Chalyk NE, Dovgalevskiy PYa, Klochkov VA, Anisimova OM, Il’in AA, Petyaev I. Value of definition the lipidokislyayushchikh of catalytic antibodies at patients with coronary heart disease. Klin Lab Diagnostika. 2009;(8):7-8. (In Russ.)
27. Lantsova VB, Sepp EK. Immunobiochemical characteristics of IgG antibodies in myasthenia. Bull Exp Biol Med. 2002 Jun;133(6):588-90.
28. Baranova SV, Buneva VN, Kharitonova MA, Sizyakina LP, Zakharova OD, Nevinskiy GA. Variety of the integraza-hydrolyzing IgG and IgM of antibodies from a blood of HIV-positive patients. Biokhimiia. 2011;74(12):1615-28. (In Russ.)
29. Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, et al. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV-infection. AIDS Res Hum Retroviruses. 2007 Dec;23(12):1541-54. doi: http://dx.doi.org/10.1089/aid.2007.0081
30. Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S. Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun Rev. 2008 Jun;7(6):473-9. doi: http://dx.doi.org/10.1016/j.autrev.2008.04.002
31. Uda T, Hifumi E. Super catalytic antibody and antigenase. J Biosci Bioeng. 2004;97(3):143-52. doi: http://dx.doi.org/10.1016/S1389-1723(04)70183-8
32. Zhil’tsov IV, Generalov II, Dotsenko ML, Matveev AA. Enzymatic activity of the drugs IgG at a viral hepatitis. Zhurn Mikrobiologii Epidemiologii Immunobiologii. 1998;(4):73-7. (In Russ.)
33. Chebodaev AK, Buneva VN, Nevinskiy GA. The DNA-hydrolyzing antibodies from a blood of patients with a viral hepatitis With. Ros Immunol Zhurn. 2015;9(1):41-55. (In Russ.)
34. Moiseeva AM, Zhil’tsov IV, Piskun DV, Generalov II, Semenov VM. Catalytic activity of immunoglobulins of a class G at patients with acute intestinal infections. Immunopatologiia Allergologiia Infektologiia. 2007;(4):63-9. (In Russ.)
35. Okulich VK. Abzimny activity of immunoglobulins at a surgical infection. Novosti Khirurgii. 2016;24(6):568-78. (In Russ.)
36. Lacroix-Desmazes S, Bayry J, Kaveri SV, Hayon-Sonsino D, Thorenoor N, Charpentier J, et al. Mallet High levels of catalytic antibodies correlate with favorable outcome in sepsis. PNAS. 2005 Mar;102(11):4109-13. doi: http://dx.doi.org/10.1073/pnas.0500586102
37. Brown EL, Nishiyama Y, Dunkle JW, Aggarwal S, Planque S, Watanabe K, et al. Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection. J Biol Chem. 2012 Mar;287(13):9940-51. doi: http://dx.doi.org/10.1074/jbc.M111.330043
38. Hifumi E, Morihara F, Hatiuchi K, Okuda T, Nishizono A, Uda T. Catalytic features and eradication ability of antibody light-chain UA15-L against Helicobacter pylori. J Biol Chem. 2008 Jan;283(2):899-907. doi: http://dx.doi.org/10.1074/jbc.M705674200
39. Matsuura K, Ohara K, Munakata H, Hifumi E, Uda T. Pathogenicity of catalytic antibodies: catalytic activity of Bence Jones proteins from myeloma patients with renal impairment can elicit cytotoxic effects. Biol Chem. 2006 May;387(5):543-8. doi: http://dx.doi.org/10.1515/BC.2006.070
40. Kozyr AV, Kolesnikov AV, Zelenova NA, Savshchenko LP, Mikhalap SV, Bulina ME, et al. Autoantibodies to nuclear antigens: correlation between cytotoxicity and DNA-hydrolyzing activity. Appl Biochem Biotechnol. 2000 Jan-Mar;83(1-3):255-68.
41. Ramaswamy H, Swamy CV, Das MR. Purification and characterization of a high molecular weight ribonuclease from human milk. J Biol Chem. 1993 Feb;268(6):4181-7.
42. Hanson LA, Hahn-Zoric M, Berndes M, Ashraf R, Herias V, Jalil F, et al. Breast feeding: overview and breast milk immunology. Acta Paediatr Jpn. 1994 Oct;36(5):557-61.
43. Kanyshkova TG, Semenov DV, Vlasov AV, Khlimankov D, Baranovskii G, Shipitsyn MV, et al. DNA- and RNA-hydrolysing antibodies in human milk and their possible biological role. Mol. Biol. 1997;31:1082-91.
44. Generalov II, Korotina OL, Tikhonova SF, Generalova AG, Zheleznyak NV. Abzimny activity of polyclonal immunoglobulins of a class A. Vestn VGMU. 2014;13(4):42-7. (In Russ.)
45. Ermakov EA, Smirnova LP, Parkhomenko TA, Dmitrenok PS, Krotenko NM, Fattakhov NS, et al. DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia. Open Biol. 2015 Sep;5(9):150064. doi: http://dx.doi.org/10.1098/rsob.150064
46. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999 Sep;5(9):1044-7.
47. Generalov II. Complex assessment of abzimny activity of polyclonal IgG at autoimmune, viral and oncologic diseases. Immunopatologiia Allergologiia Infektologiia. 2000;(3):7-12. (In Russ.)
48. Landry DW, Yang GX. Anti-cocaine catalytic antibodies – a novel approach to the problem of addiction. J Addict Dis. 1997;16(3):1-17. doi: http://dx.doi.org/10.1300/J069v16n03_01
49. Wang J, Han Y, Liang S, Wilkinson MF. Catalytic antibody therapy against the insecticide carbaryl. Biochem Biophys Res Commun. 2002 Mar;291(3):605-10. doi: http://dx.doi.org/10.1006/bbrc.2002.6484
50. Nishi Y. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology. Curr Pharm Des. 2003;9(26):2113-30.
51. Sharma SK, Bagshawe KD. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination. Expert Opin Biol Ther. 2017 Jan;17(1):1-13.
52. Shabat D, Lode HN, Pertl U, Reisfeld RA, Rader C, Lerner RA, et al. In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci USA. 2001;98(13):7528-33. doi: http://dx.doi.org/10.1073/pnas.131187998
53. Hifumi E, Arakawa M, Matsumoto S, Yamamoto T, Katayama Y, Uda T. Biochemical features and antiviral activity of a monomeric catalytic antibody light-chain 23D4 against influenza A virus. FASEB J. 2015 Jun;29(6):2347-58. doi: http://dx.doi.org/10.1096/fj.14-264275
54. Worrall DS, McDunn JE, List B, Reichart D, Hevener A, Gustafson T. Synthesis of an organoinsulin molecule that can be activated by antibody catalysisю Proc Natl Acad Sci U S A. 2001 Nov;98(24):13514-8. doi: http://dx.doi.org/10.1073/pnas.241516698
55. Ruzina ND, Ponomarenko NA, Belogurov AA, Friboulet A, Kimova MV, Misikov VK, i dr. Phenomenon of specificity and functionality of an antitelooposredovanny proteolysis and its role in demyelination mechanisms. Molekuliar Meditsina. 2010;(2):27-39. (In Russ.)
56. Ostler EL, Resmini M, Brocklehurst K, Gallacher G. Polyclonal catalytic antibodies. J Immunol Methods. 2002 Nov;269(1-2):111-24.
57. Gallacher G, Jackson CS, Searcey M, Goel R, Mellor GW, Smith CZ, et al. Catalytic antibody activity elicited by active immunisation. Evidence for natural variation involving preferential stabilization of the transition state. Eur J Biochem. 1993 May;214(1):197-207.
Information about authors:
Zherulik S.V. – postgraduate of the Chair of Oncology with the course of Radiodiagnosis and the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
Lud N.G. – Doctor of Medical Sciences, professor, head of the Chair of Oncology with the course of Radiodiagnosis and the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
Generalov I.I. – Doctor of Medical Sciences, professor, head of the Chair of Clinical Microbiology, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 210023, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Oncology with the course of Radiodiagnosis and the course of the Faculty for Advanced Training & Retraining. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Sophia V. Zherulik.
